|
Novel
Method for Inducing Tissue Repair
Inventors:
Meenhard Herlyn
and Mark Nesbit
Tech ID:
HM-96001
Description:
The healing of open wounds or replacement of lost tissue following
injury, reconstructive surgery, transplantation or loss of blood
supply requires the formation of new blood vessels as well as the
growth of organized tissue. At present there are no reproducible
procedures to speed up tissue growth, which requires formation of
extracellular matrix and collagens by activated fibroblasts, and
to induce new blood vessel formation. Recombinant tissue growth
factors have been utilized for this purpose with limited success
due to their short half-life in vivo, limited penetration into deeper
tissue regions, and difficulty in application directly to naturally
healing tissue.
Wistar scientists have constructed replication-defective
recombinant adenoviruses which express platelet-derived growth factor
B (PDGF-B), vascular endothelial growth factor (VEGF) as well as
other growth factors. Clinical trials of these vectors to enhance
wound healing in diabetic ulcers have been planned; additional applications
of the technology, including the use of the vectors in tissue engineering
are in development.
Key Words:
Therapeutic, dermatologic, wound healing, tissue engineering
Applications
and Advantages: Following simple injection, these viruses
can induce the formation of either blood vessels (VEGF) or new stromal
tissue (PDGF-B). The stimulation in vivo is self-limiting because
the viruses are replication defective. These viruses may be useful
for inducing wound healing and tissue repair in a variety of situations,
including wound healing, reconstructive surgery and transplantation.
Intellectual
Property Status:This technology is described in PCT/US/98/04487
("Methods and compositions for healing tissue defects and inducing
hypervascularity in mammalian tissue"). US and international
patents are pending.
Licensing
Opportunity: Wistar is seeking
an exclusive licensee and/or sponsored
research to support the development of
this technology.
Contact:
Meryle
J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org
Last updated: Aug.
02
|
